These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 19020876)
1. Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study. Mäenpää J; Leminen A Cancer Chemother Pharmacol; 2009 Jul; 64(2):297-300. PubMed ID: 19020876 [TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885 [TBL] [Abstract][Full Text] [Related]
5. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy. Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477 [TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627 [TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Pfisterer J; du Bois A; Wagner U; Quaas J; Blohmer JU; Wallwiener D; Hilpert F; Gynecol Oncol; 2004 Mar; 92(3):949-56. PubMed ID: 14984965 [TBL] [Abstract][Full Text] [Related]
15. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer. Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer. Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]